Related Experiment Video
Updated: Aug 6, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Perspectives for a hepatitis C virus vaccine
1IRIS Research Centre, Chiron S.p.A., Siena, Italy. abrignani@iris02.biocine.it
Clinical and Diagnostic Virology
|September 19, 1998
Summary
Developing a hepatitis C virus (HCV) vaccine shows promise. Immunizing chimpanzees with HCV E1/E2 proteins generated neutralizing antibodies and protected against chronic infection, suggesting a potential vaccine strategy.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Hepatitis C virus (HCV) infection often leads to chronic illness due to poor natural immunity.
- Despite immune responses to HCV proteins, a vaccine remains unavailable, with high annual incidence in the USA.
Purpose of the Study:
- To explore strategies for overcoming challenges in developing an HCV vaccine.
- To report recent advancements in HCV vaccine development.
Main Methods:
- Development of a cytofluorimetric assay (neutralization of binding or NOB assay) to measure antibodies neutralizing HCV E2 glycoprotein binding to human cells.
- Assessment of NOB antibody levels in vaccinated and carrier chimpanzees.
Main Results:
- Most chimpanzees challenged with HCV showed low levels of NOB antibodies.
- Chimpanzees immunized with E1/E2 heterodimer developed NOB antibodies and high neutralizing antibody titers.
- Vaccinated chimpanzees were protected from chronic infection but not initial challenge by a heterologous virus.
Conclusions:
- A subunit vaccine using recombinant HCV proteins may offer protection against infection and chronic infection across different HCV genotypes.
Related Concept Videos
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...